Cabotegravir (CAB) tablet clinical trials

Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

This study looks at whether switching from daily tablets to monthly injections can keep HIV under control in adults. It's for people whose HIV is already well-managed with current medication, testing a new long-acting injectable treatment.